Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.

Brianna C Peacock Sanjna Tripathy Hannah L HananiaHannah Y WangZsila S Sadighi Anisha B Patel

Published in: Journal of neuro-oncology (2024)

Improvement in characterization of MEKi toxicities and their management is important to develop treatment guidelines for pediatric and young adult patients with NF1 on MEKi therapy.

Keyphrases

young adults
signaling pathway
childhood cancer
oxidative stress
lps induced
clinical practice
nuclear factor
middle aged
immune response
pi k akt
replacement therapy
toll like receptor
inflammatory response
cell therapy